Slide 1: Advancing a new male infertility treatment
For personal use only Advancing a new male infertility treatment Alison Coutts Executive Chairman Memphasys Limited 7/08/2017 www.memphasys.com 1
Slide 2: Disclaimer
Disclaimer For personal use only This presentation is not and does not form part of any offer, invitation or recommendation in respect of securities. Any decision to buy or sell Memphasys securities or other products should be made only after seeking appropriate financial advice. Reliance should not
Slide 3: Core Asset: Bio-Separations Intellectual Property
Core Asset: Bio-Separations Intellectual Property First Application: Male Infertility Treatment For personal use only • Memphasys has unique, patented IP for separating valuable cells and molecules from biological fluids (“Bio-Separations”) • The most commercially advanced application, developed wit
Slide 4: Addressed Market Need: Male Infertility
Addressed Market Need: Male Infertility For personal use only • Clinical need to reduce male factor contribution to couple infertility (presently at ~40%) • Need to decrease ART1 financial and emotional cost by decreasing o No. of procedures required o Patient angst associated with ART o Cost per pr
Slide 5: Problems with current sperm selection processes
Problems with current sperm selection processes For personal use only - ; Density Gradient Centrifuge, “DGC” ‘Swim Up’ (Used for IVF and IUI) (Used for ICSI) Slow, laborious lab processes ( ~40 minutes) Quite laborious (~30 minutes) Damages sperm DNA: Requires motile sperm less pregnancies less
Slide 6: Felix: Memphasys' product to address male factor infertility
Felix: Memphasys’ product to address male factor infertility For personal use only Felix, MEM’s lead product program, is a device to prepare sperm for use in artificial reproduction Felix re-usable cartridge prototype Felix ‘fast prototype’ device, & single-use cartridge 7/08/2017 www.memphasys.com
Slide 7: Prototype cartridge performance on healthy human ejaculate
Prototype cartridge performance on healthy human ejaculate For personal use only Sample before treatment After treatment - 6 minutes Macrocephalic sperm (large head) • Separation of viable sperm ; no debris Dead sperm Viable sperm • Intact membranes and acrosomes • Higher average motility • Reduced
Slide 8: Market Size: Human ART Market
Market Size: Human ART Market For personal use only • ART Market size: - Initial accessible market (IVF, ICSI): $600 million (est) - Plus IUI1 market: $1.2 billion Other Human ART Market Data Couples with fertility issues >50 m Australian couples seeking 1VF treatments 1 in 6 IVF clinics globally ~4
Slide 9: Felix Commercialisation Plan
Felix Commercialisation Plan For personal use only • Finish in-vitro testing of current cartridge by the 3* Australian IVF centre partners • Develop and commercialise “fast prototype” device (with disposable cartridge) o Build devices for in-vitro assessment by ~15 leading IVF centres in the world –
Slide 10: Indicative Felix Key Milestones and Cumulative Costs
Indicative Felix Key Milestones and Cumulative Costs For personal use only (Excludes corporate overheads and other R&D programs) $2.70m - Start of publications and presentations; - Felix International clinical system launch - Finish of 15-site intl. KOL study $1.25m $0.425m - 20 “fast prototypes” re
Slide 11: Corporate Statistics
Corporate Statistics For personal use only • Shares on issue: 700m Top 5 Shareholders % Holding Andrew Goodall 33.8% Mark Gell 3.2% Bridge Road Capital 2.9% B Arthur Superannuation Fund 2.9% Stephen Gaffney 2.5% • Estimated funding required next 12 months: ~$3m Anticipated Use of Funds $m Felix deve